Joseph Catanzaro
Stock Analyst at Mizuho
(3.79)
# 629
Out of 5,149 analysts
105
Total ratings
44.83%
Success rate
11.29%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EIKN Eikon Therapeutics | Initiates: Outperform | $26 | $14.98 | +73.56% | 1 | Mar 2, 2026 | |
| TNGX Tango Therapeutics | Initiates: Outperform | $19 | $12.12 | +56.77% | 2 | Feb 23, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $32 → $35 | $16.02 | +118.55% | 5 | Jan 29, 2026 | |
| IBRX ImmunityBio | Maintains: Overweight | $5 → $7 | $9.32 | -24.89% | 6 | Jan 20, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $6.5 → $10 | $4.98 | +100.80% | 6 | Jan 20, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $90 → $143 | $101.65 | +40.68% | 4 | Jan 13, 2026 | |
| AVTX Avalo Therapeutics | Initiates: Outperform | $39 | $18.39 | +112.07% | 1 | Dec 18, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $51 | $7.57 | +573.71% | 1 | Dec 18, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Neutral | $18 | $18.51 | -2.76% | 1 | Dec 18, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $53 | $41.45 | +27.86% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $120 | $85.97 | +39.58% | 2 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $29.75 | +61.34% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $105 | $72.18 | +45.48% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7.5 → $6 | $4.17 | +43.88% | 10 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $45 | $13.12 | +242.99% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $147.98 | -25.67% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $41.09 | -7.52% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $13.47 | +11.36% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $69.74 | -24.00% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $1.96 | +409.63% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.37 | +1,291.94% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $10.19 | +86.46% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.44 | +514.75% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $12.82 | +180.92% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $11.42 | +250.26% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $10.81 | +38.76% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $2.58 | +74.42% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.65 | +1,718.18% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.15 | +1,642.16% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $2.66 | -34.13% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $24.30 | -17.70% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.55 | -41.18% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $29.16 | +585.87% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $17.33 | +101.96% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.43 | +4,095.80% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.34 | +669.23% | 3 | Apr 7, 2020 |
Eikon Therapeutics
Mar 2, 2026
Initiates: Outperform
Price Target: $26
Current: $14.98
Upside: +73.56%
Tango Therapeutics
Feb 23, 2026
Initiates: Outperform
Price Target: $19
Current: $12.12
Upside: +56.77%
Nurix Therapeutics
Jan 29, 2026
Maintains: Overweight
Price Target: $32 → $35
Current: $16.02
Upside: +118.55%
ImmunityBio
Jan 20, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $9.32
Upside: -24.89%
CytomX Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $6.5 → $10
Current: $4.98
Upside: +100.80%
Revolution Medicines
Jan 13, 2026
Maintains: Outperform
Price Target: $90 → $143
Current: $101.65
Upside: +40.68%
Avalo Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $39
Current: $18.39
Upside: +112.07%
Upstream Bio
Dec 18, 2025
Initiates: Outperform
Price Target: $51
Current: $7.57
Upside: +573.71%
Bicara Therapeutics
Dec 18, 2025
Initiates: Neutral
Price Target: $18
Current: $18.51
Upside: -2.76%
Spyre Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $53
Current: $41.45
Upside: +27.86%
Dec 11, 2025
Maintains: Outperform
Price Target: $81 → $120
Current: $85.97
Upside: +39.58%
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $29.75
Upside: +61.34%
Oct 21, 2025
Initiates: Outperform
Price Target: $105
Current: $72.18
Upside: +45.48%
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $4.17
Upside: +43.88%
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $13.12
Upside: +242.99%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $147.98
Upside: -25.67%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $41.09
Upside: -7.52%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $13.47
Upside: +11.36%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $69.74
Upside: -24.00%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $1.96
Upside: +409.63%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.37
Upside: +1,291.94%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $10.19
Upside: +86.46%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.44
Upside: +514.75%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $12.82
Upside: +180.92%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $11.42
Upside: +250.26%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $10.81
Upside: +38.76%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $2.58
Upside: +74.42%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.65
Upside: +1,718.18%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.15
Upside: +1,642.16%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $2.66
Upside: -34.13%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $24.30
Upside: -17.70%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.55
Upside: -41.18%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $29.16
Upside: +585.87%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $17.33
Upside: +101.96%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.43
Upside: +4,095.80%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.34
Upside: +669.23%